RxDoctor Payments Data

Oscar Reyna, MD

General Practice · Latrobe, PANPI 1063408706

Payments from drug & device makers

$2,824in general payments, 2019–2025

Across 128 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$926
  • AstraZeneca$447
  • Biohaven Pharmaceutical Holding Company Ltd.$361
  • Biohaven Pharmaceuticals, Inc.$282
  • Novo Nordisk$146
  • Johnson & Johnson$117
  • plus $546 from 7 others

What the payments were for

  • Food & beverage$2,824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,824 in reported general payments places this provider in the 95th percentile of 3,208 general practice providers in Pennsylvania.

See all general practice providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,428
Medicare patients
99
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$136,277
JardianceEmpagliflozin66$65,343
XareltoRivaroxaban76$60,009
EliquisApixaban41$48,208
TrulicityDulaglutide20$38,718
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$32,022
FarxigaDapagliflozin Propanediol23$30,702
JanuviaSitagliptin Phosphate13$15,484
Lagevrio (Eua)Molnupiravir23$12,447
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$12,273
VascepaIcosapent Ethyl13$12,141
Repatha SureclickEvolocumab15$11,445
MyrbetriqMirabegron16$9,047
Breo ElliptaFluticasone/Vilanterol15$7,244
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$5,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$146$136,277121 claims
Johnson & JohnsonXarelto$117$60,00976 claims
PfizerEliquis$92$48,20841 claims
AstraZenecaFarxiga$447$30,70223 claims
AbbVieSynthroid$926$2,95743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,208 general practice providers in Pennsylvania.

Other general practice in Latrobe

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →